| Company Name: |
Shanghai Tauto Biotech Co., Ltd.
|
| Tel: |
021-51320588 |
| Email: |
tauto@tautobiotech.com |
| Products Intro: |
Product Name:Buddlejasaponin IV
CAS:139523-30-1
Purity:98% Package:10mg;20mg;1gm;5gm;10gm;1KG
|
| Company Name: |
Wuhan ChemFaces Biochemical Co., Ltd.
|
| Tel: |
18607101326 15172504745 |
| Email: |
aileen@chemfaces.com |
| Products Intro: |
Product Name:Buddlejasaponin IV
CAS:139523-30-1
Purity:>=98% Package:5mg ,10mg ,20mg ,50mg ,100mg; 200mg; 500mg,可根据客户需求定制 Remarks:1908/10mg
|
|
| | buddlejasaponin IV Basic information |
| Product Name: | buddlejasaponin IV | | Synonyms: | buddlejasaponin IV;[(4R)-13,28-Epoxy-16β,23-dihydroxyolean-11-en-3β-yl]2-O,3-O-bis(β-D-glucopyranosyl)-6-deoxy-β-D-galactopyranoside;[(4R)-16β,23-Dihydroxy-13,28-epoxyoleana-11-ene-3β-yl]6-deoxy-2-O,3-O-bis(β-D-glucopyranosyl)-β-D-galactopyranoside;Saikosaponin 1;Buddleoglucoside IV;β-D-Galactopyranoside, (3β,4α,16β)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl O-β-D-glucopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-6-deoxy- | | CAS: | 139523-30-1 | | MF: | C48H78O18 | | MW: | 943.12 | | EINECS: | | | Product Categories: | | | Mol File: | 139523-30-1.mol |  |
| | buddlejasaponin IV Chemical Properties |
| Melting point | 288-290℃ | | density | 1.43±0.1 g/cm3 (20 ºC 760 Torr) | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | powder | | pka | 12.886±0.70(predicted) | | color | White |
| | buddlejasaponin IV Usage And Synthesis |
| Uses | Buddlejasaponin IV (BS‐IV) exerts anti-inflammatory and cytotoxic effects against cancer cells[1]. | | target | P21 | Chk | Akt | PARP | Caspase | Bcl-2/Bax | p53 | NOS | COX | IL Receptor | TNF-α | NF-kB | MAPK | | References | [1] Young Sun Hwang, et al. Buddlejasaponin IV induces cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes. Phytother Res. 2011 Oct;25(10):1503-10. DOI:10.1002/ptr.3406
[2] Jong-Heon Won, et al. Anti-inflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol. 2006 May;148(2):216-25. DOI:10.1038/sj.bjp.0706718 |
| | buddlejasaponin IV Preparation Products And Raw materials |
|